NCT03861793 · Interventional trial
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Overall registry status Completed
Phase 1 · Phase 2
Conditions Advanced Solid Tumors
Delaware Valley sites
- Mural Oncology Investigational Site · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory